Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database.
acquired hemophilia
drugs
pharmacovigilance
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
revised:
21
10
2022
received:
18
08
2022
accepted:
27
10
2022
pubmed:
12
11
2022
medline:
25
1
2023
entrez:
11
11
2022
Statut:
ppublish
Résumé
Acquired hemophilia A (AHA) is a rare autoimmune hemorrhagic disease occurring in several underlying conditions. Drug-associated AHA (D-AHA) is poorly addressed nowadays. This work aims to identify and characterize which drugs are associated with AHA using the WHO global database of reported potential effects of medicinal products (VigiBase). First, we realized a disproportionality analysis using the information component (IC) to identify D-AHA in VigiBase. IC compares observed- and expected-values in order to find associations between drugs and adverse drug reactions (ADRs) using disproportionate Bayesian reporting. IC 14 drugs with IC This worldwide pharmaco-epidemiologic study updates the list of the drugs associated with AHA. The clinician should be aware of these possible severe ADR, which might require larger epidemiological and pathophysiologic studies.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
186-192Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Kruse-Jarres R, Kempton CL, Baudo F et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017;92:695-705.
Franchini M, Lippi G. Acquired hemophilia A. Adv Clin Chem. 2011;54: 71-80.
Michiels JJ, Hamulyak K, Nieuwenhuis HK, Novakova I, Van Vliet HHDM. Acquired haemophilia A in women postpartum: management of bleeding episodes and natural history of the factor VIII inhibitor. Eur J Haematol. 1997;59:105-109.
Knoebl P, Marco P, Baudo F et al. Demographic and clinical data in acquired hemophilia A: results from the european acquired haemophilia registry (EACH2): demographics of acquired hemophilia A. J Thromb Haemost. 2012;10(4):622-631.
Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol. 2005;80(1):55-63.
O'Reilly RA, Hamilton RD. Acquired hemophilia, meningioma, and diphenylhydantoin therapy. J Neurosurg. 1980;53(5):600-605.
Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Drug Information J. 2008; 42(5):409-419.
Bate A, Lindquist M, Edwards IR et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4): 315-321.
Franchini M, Capra F, Nicolini N et al. Drug-Induced anti-factor VIII antibodies: a systematic review. Med Sci Monit. 2007;13(4):55-61.
Österborg A, Karlsson C, Lundin J, Kimby E, Mellstedt H. Strategies in the management of alemtuzumab-related side effects. Sem Oncol. 2006;33:29-35.
Yap SM, Dillon M, Crowley RK, McGuigan C. Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset. Mult Scler J Exp Transl Clin. 2020;6(2):1-6.
Limb, SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol. 2007;120(6):1378-1381.
Balbino B, Herviou P, Godon O et al. The Anti-IgE MAb omalizumab induces adverse reactions by engaging Fcγ receptors. J Clin Invest. 2020;130(3):1330-1335.
Scott LJ. Sitagliptin: a review in type 2 diabetes. Drugs. 2017;77(2):209-224.
Ahrén B, Johnson SL, Stewart M, et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Dia Care. 2014;37(8):2141-2148.
Sulkowski MS, Cooper C, Hunyady B et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8(4):212-223.
Crotty S, Cameron C, Andino R. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med. 2002;80(2):86-95.
Takeyama M, Nogami N, Kajimoto T, Ogiwara K, Matsumoto T, Shima M. First report of real-time monitoring of coagulation function potential and IgG subtype of anti-FVIII autoantibodies in a child with acquired hemophilia A associated with streptococcal infection and amoxicillin. Int J Hematol. 2018;107(1):112-116.
Lemoine C, Giacobbe AG, Bonifacino E, Karapetyan L, Seaman C. A case of acquired haemophilia A in a 70-year-old post COVID-19 vaccine. Haemophilia. 2021;1:1-3.
Mansoor R, Sara F. A case report of acquired hemophilia following COVID-19 vaccine. J Thromb Haemost. 2021;19(6):1515-1518.
Andrew J P, Cassandra S, Rebecca KJ, Terry G, Janis A. Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination. Blood Advances. 2021;5(13):2794-2798.
Files JK, Boppana S, Perez MD, et al. Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. J Clin Invest. 2021;131(1):e140491.
Mahendra A, Padiolleau- Lefevre S, Kaveri SV, Lacroix- Desmazes S. Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A? Br J Haematol. 2012;156(1):3-12.
Lee EJ, Cines DB, Gernsheimer T, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021;96(5):534-537.
Hirsiger JR, Martinez M, Tsakiris DA et al. Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID-19 vaccines. J Thromb Haemost. 2022;20(4):1015-1018. https://doi.org/10.1111/jth.15665. [Epub ahead of print]
Moore D, Elmes J, Arnall J, et al. Immune checkpoint inhibitor-induced acquired haemophilia: a pharmacovigilance analysis of the FDA adverse event reporting system. Haemophilia. 2022;28:e145-e148. https://doi.org/10.1111/hae.14632. [Epub ahead of print]
Goldman SA. Limitations and Strengths of spontaneous reports data. Clin Ther. 1998;20:C40-C44.